Cable Hill Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Cable Hill Partners’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-200	Closed	-$2K	–	926
2017 Q4	$2K	Sell	200 -329	-62%	-$3.42K	﹤0.01%	868
2017 Q3	$7K	Sell	529 -13	-2%	-$192	﹤0.01%	678
2017 Q2	$9K	Sell	542 -2	-0.4%	-$31	﹤0.01%	431
2017 Q1	$8K	Sell	544 -31	-5%	-$460	﹤0.01%	445
2016 Q4	$8K	Buy	575 +65	+13%	+$1.04K	﹤0.01%	452
2016 Q3	$9K	Sell	510 -53	-9%	-$853	0.01%	449
2016 Q2	$9K	Hold	563	–	–	0.01%	388
2016 Q1	$8K	Buy	+563	New	+$5.9K	0.01%	385

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UIM

USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

CLM

ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Cable Hill Partners's LXRX Position: Q1 2018 in Review

Cable Hill Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2018, closing a stake of 200 shares — an estimated $2K sold.

Cable Hill Partners first reported a position in LXRX in Q1 2016 and held it in 8 quarters. The position peaked at $9K in Q2 2017. 126 funds tracked by Wall St. Rank hold LXRX as of Q1 2018.

Cable Hill Partners reported no remaining Lexicon Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Cable Hill Partners sold 200 Lexicon Pharmaceuticals shares in Q1 2018, an estimated $2K.
Cable Hill Partners first reported a position in Lexicon Pharmaceuticals in Q1 2016 and held it in 8 quarters.
Cable Hill Partners's Lexicon Pharmaceuticals position peaked at $9K in Q2 2017.
126 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.